Pharmacodynamic modeling for change of locomotor activity by methylphenidate in rats

被引:15
作者
Aoyama, T [1 ]
Yamamoto, K
Kotaki, H
Sawada, Y
Iga, T
机构
[1] Tokyo Univ Hosp, Fac Med, Dept Pharm, Bunkyo Ku, Tokyo 113, Japan
[2] Univ Kyusyu, Fac Pharmaceut Sci, Dept Pharmaceut, Higashi Ku, Fukuoka 81282, Japan
关键词
methylphenidate; rats; locomotor activity; pharmacodynamic modeling; Emax model;
D O I
10.1023/A:1012186519946
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The locomotive activity changes after intravenous (i.v.) administration of methylphenidate (MPD) in rats were pharmacodynamically analyzed. Methods. MPD concentration in plasma, MPD concentration and dopamine (DA) level in striatal dialysate collected by microdialysis method, and the locomotor activity after i.v. administration of MPD (2, 5 and 10 mg/kg doses) were used for the analysis. Results, The transport of MPD from plasma to the interstitial fluid in the brain could be expressed by the linear two-compartment model. The clockwise hysteresis between the MPD concentration and the DA level in the dialysate could be explained by the pharmacodynamic model considering Michaelis-Menten type reuptake process of the extracellular DA into the terminal of the dopaminergic nerve and its competitive inhibition by the extracellular MPD. The inhibition constant (K-i) of MPD for DA reuptake was estimated to be 41.3 +/- 73.8 nM (mean +/- SE), which was closely consistent with the in vitro value after correction with dialysis recovery. The relationship between DA level in dialysate and locomotor activity was expressed by the Emax model considering two contrary effects, hyperkinesia and stereotypy. The bi-phasic locomotor activity-time profiles after high dose of MPD could be represented by this model. Conclusions. The developed model made it possible to explain the tolerance in DA increase and the complicated locomotive change induced by MPD, and may be useful for other DA reuptake inhibitors, such as amphetamine and methamphetamine.
引用
收藏
页码:1601 / 1606
页数:6
相关论文
共 20 条
[2]   STEREOSPECIFIC DISTRIBUTION OF METHYLPHENIDATE ENANTIOMERS IN RAT-BRAIN - SPECIFIC BINDING TO DOPAMINE REUPTAKE SITES [J].
AOYAMA, T ;
KOTAKI, H ;
SAWADA, Y ;
IGA, T .
PHARMACEUTICAL RESEARCH, 1994, 11 (03) :407-411
[3]   Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats [J].
Aoyama, T ;
Kotaki, H ;
Sawada, Y ;
Iga, T .
PSYCHOPHARMACOLOGY, 1996, 127 (02) :117-122
[4]   PHARMACOKINETICS AND PHARMACODYNAMICS OF (+)-THREO-METHYLPHENIDATE ENANTIOMER IN PATIENTS WITH HYPERSOMNIA [J].
AOYAMA, T ;
SASAKI, T ;
KOTAKI, H ;
SAWADA, Y ;
SUDOH, Y ;
HONDA, Y ;
IGA, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (03) :270-276
[5]   REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE-CHILDREN [J].
BARKLEY, RA .
JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 1977, 18 (02) :137-165
[6]   HIGH-AFFINITY [H-3] GBR 12783 BINDING TO A SPECIFIC SITE ASSOCIATED WITH THE NEURONAL DOPAMINE UPTAKE COMPLEX IN THE CENTRAL-NERVOUS-SYSTEM [J].
BONNET, JJ ;
PROTAIS, P ;
CHAGRAOUI, A ;
COSTENTIN, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 126 (03) :211-222
[7]   CHARACTERIZATION OF METHYLPHENIDATE AND NOMIFENSINE INDUCED DOPAMINE RELEASE IN RAT STRIATUM USING INVIVO BRAIN MICRODIALYSIS [J].
BUTCHER, SP ;
LIPTROT, J ;
ABURTHNOTT, GW .
NEUROSCIENCE LETTERS, 1991, 122 (02) :245-248
[8]   KINETICS OF COCAINE DISTRIBUTION, ELIMINATION, AND CHRONOTROPIC EFFECTS [J].
CHOW, MJ ;
AMBRE, JJ ;
RUO, TI ;
ATKINSON, AJ ;
BOWSHER, DJ ;
FISCHMAN, MW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (03) :318-324
[9]  
COWAN A, 1971, BRIT J PHARMACOL, V43, P461
[10]  
DALY DD, 1956, P STAFF M MAYO CLIN, V31, P620